1[1]Theofilopoulos AN, Kono DH. The genes of systemic autoimmunity. Proc Assoc Am Physicians, 1999,111(3) :228 - 240.
2[2]Rieux-Laucat F, Le Deist E, Hivroz C, et al. Mutations in Fasassociated with human lymphoproliferative syndrome and autoimmunity. Science, 1995, 268(5215): 1347 - 1349.
3[3]Wu J, Wilson j, He j, et al, Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest, 1996,98(5) :1107- 1113.
4[4]Vaishnaw AK, Toubi E, Ohsako S, et al. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95(Fas/APO - 1) mutations. Arthritis Rheum, 1999,42(9):1833 - 1842.
5[5]Courtney PA, Crockard AD, Williamson K, et al. Lymphocyte apoptosis in systemic lupus erythematosus:relationships with Fas expression, serum soluble Fas and disease activity. Lupus, 1999,8(7) :508 - 513.
6[6]Al-Maini MH, Mountz JD, Al-Mohri HA, et al. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus.Lupus, 2000,9(2): 132 - 139.
7[7]Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol, 1994, 152(7):3685 - 3692.
8[8]Richardson BC, Yung RL, Johnson KJ, et al. Monocyte apoptosis in patients with active lupus. Arthritis Rheum, 1996,39 (8): 1432 - 1434.
9[9]Lopez - Hoyos M, Carrio R, Merino R, et al. Constitutive expression of bcl - 2in B cells causes alethal form of lupuslike autoimmune disease after induction of neonatal tolerance to H- 2b alloantigens. JExp Med, 1996, 183 (6):2523 - 2531.
